Obinutuzumab
- CAS No.
- 949142-50-1
- Chemical Name:
- Obinutuzumab
- Synonyms
- Ga 101;Ro5072759;afutuzumab;Ro 5072759;Humab(cd20);Obinutuzumab;Obinutuzumab/afutuzumab;Obinutuzumab (anti-CD20);Research Grade Obinutuzumab(DHC90704);Inhibitor,GA 101,Anti-Human CD20 type II, Humanized Antibody,inhibit,GA101,Obinutuzumab,GA-101
- CBNumber:
- CB81518489
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MFCD00211769
- MOL File:
- Mol file
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | O43472U9X8 |
SAFETY
Risk and Safety Statements
| Hazardous Substances Data | 949142-50-1(Hazardous Substances Data) |
|---|
Obinutuzumab Chemical Properties,Uses,Production
Description
In November 2013, the US FDA approved the glycoengineered, type II anti-CD20 antibody obinutuzumab (also known as GA101) in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab is the first drug approved under the FDA’s breakthrough therapy designation, created in 2012 to quicken the pace of development and review of drugs for serious conditions. The Fc portion of obinutuzumab was glycoengineered to reduce fucosylation of the Fc carbohydrate, resulting in increased FcγRIIIa affinity and antibody-dependent cellular cytotoxicity (ADCC) potency. As expected for a type II antibody, obinutuzumab demonstrated lower complement-mediated cytotoxicity, more potent mediation of cell death via the nonclassical apoptosis pathway and increased ADCC as compared with rituximab in preclinical studies. In addition, obinutuzumab induced a stronger antitumor effect in mouse xenograft models of human lymphoma than rituximab and ofatumumab, supporting clinical investigation of this third generation anti-CD20 antibody.
Originator
GlycArt Biotechnology AG (United States)
brand name
Gazyva
Obinutuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Obinutuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32161 | 58 |
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38631 | 58 | |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | masar@topule.com | China | 8467 | 58 |
| Aladdin Scientific | +1-+1(833)-552-7181 | sales@aladdinsci.com | United States | 57505 | 58 |
| Wuhan Sunrise Technology Development Co., Ltd. | 27-027-83314682 13554138826 | whsrtech@vip.163.com | China | 230 | 62 |
| Dalian Meilun Biotech Co., Ltd. | 0411-62910999 13889544652 | sales@meilune.com | China | 4727 | 58 |
| LUCKY PHARMA CO., LIMITED | 0571-86403260 86403970 | lucky@lkbiology.com | China | 243 | 58 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9806 | 58 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8011 | 62 |
| Twochem Co.Ltd. | 021-58111628 15800915896 | sales@twochem.com | China | 1788 | 58 |
View Lastest Price from Obinutuzumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-11-19 | Obinutuzumab
949142-50-1
|
US $739.00-247.00 / mg | 99.4% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Obinutuzumab
949142-50-1
- US $739.00-247.00 / mg
- 99.4% (SEC-HPLC)
- TargetMol Chemicals Inc.